Pediatrix Medical reported second-quarter 2026 results with revenue of $487.8 million and net income of $39.8 million, or $0.49 per diluted share. On a non-GAAP basis the company reported Adjusted EPS of $0.63 and Adjusted EBITDA of $76.4 million for the quarter. The company reaffirmed full-year 2026 Adjusted EBITDA guidance of $280 million to $300 million.

Financial Highlights

  • Net revenue: $487.8 million for the three months ended June 30, 2026 (up from $468.8 million in prior-year period).
  • Net income: $39.8 million for the quarter; diluted net income per share $0.49 (based on 81.4 million weighted average diluted shares).
  • Adjusted EBITDA: $76.4 million for the quarter (three months ended June 30, 2026).
  • Adjusted diluted EPS: $0.63 for the quarter (non-GAAP, as defined by the company).
  • Six months: revenue $964.0 million, net income $69.4 million, Adjusted EBITDA $134.6 million, and Adjusted EPS $1.07.

Business Highlights

  • Revenue growth drivers: 4.0% year-over-year net revenue increase for the quarter, reflecting 2.1% growth from non-same unit activity (recent acquisitions) and 1.9% same-unit revenue growth.
  • Reimbursement and payer mix: Same-unit reimbursement-related revenue increased 4.0% year-over-year, driven by improved cash collections, a favorable shift toward commercial and non-government payors (+135 basis points) and higher patient acuity, mainly in neonatology.
  • Patient volume trends: Same-unit patient volume contributed a 2.1% decline to revenue; NICU days decreased 3.2% year-over-year for the quarter.
  • Cost and operational changes: Practice salaries and benefits rose due to higher same-unit clinical salaries and malpractice expense; general and administrative expenses increased reflecting executive transition costs and higher cash collection expense.
  • Transformation activities: Increased transformational and restructuring expenses related to revenue cycle management transition activities in the quarter.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.